145 related articles for article (PubMed ID: 33459254)
1. An Optimized Process for the Preparation of Aqueous Ferric Carboxymaltose: Synthesis and Structural Characterization.
Tabasi O; Razlighi MR; Darbandi MA
Pharm Nanotechnol; 2021; 9(2):157-163. PubMed ID: 33459254
[TBL] [Abstract][Full Text] [Related]
2. Iron-carbohydrate complexes treating iron anaemia: Understanding the nano-structure and interactions with proteins through orthogonal characterisation.
Krupnik L; Avaro J; Liebi M; Anaraki NI; Kohlbrecher J; Sologubenko A; Handschin S; Rzepiela AJ; Appel C; Totu T; Blanchet CE; Alston AEB; Digigow R; Philipp E; Flühmann B; Silva BFB; Neels A; Wick P
J Control Release; 2024 Apr; 368():566-579. PubMed ID: 38438093
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
4. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Funk F; Ryle P; Canclini C; Neiser S; Geisser P
Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
[TBL] [Abstract][Full Text] [Related]
5. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
[TBL] [Abstract][Full Text] [Related]
6. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
7. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.
Toblli JE; Cao G; Rico L; Angerosa M
Drug Des Devel Ther; 2017; 11():3401-3412. PubMed ID: 29238166
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD).
Fütterer S; Andrusenko I; Kolb U; Hofmeister W; Langguth P
J Pharm Biomed Anal; 2013 Dec; 86():151-60. PubMed ID: 23998966
[TBL] [Abstract][Full Text] [Related]
10. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
11. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
12. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
Bailie GR
Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
15. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre.
Tan MLN; Windscheif PM; Thornton G; Gaynor E; Rodrigues A; Howarth L
Eur J Pediatr; 2017 Oct; 176(10):1419-1423. PubMed ID: 28844092
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Barot BS; Parejiya PB; Mehta DM; Shelat PK; Shah GB
Pharm Dev Technol; 2014 Aug; 19(5):513-20. PubMed ID: 23701359
[TBL] [Abstract][Full Text] [Related]
17. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Toblli JE; Angerosa M
Drug Des Devel Ther; 2014; 8():2475-91. PubMed ID: 25525337
[TBL] [Abstract][Full Text] [Related]
18. Green synthesis and characterization of iron oxide nanoparticles using Ficus carica (common fig) dried fruit extract.
Aksu Demirezen D; Yıldız YŞ; Yılmaz Ş; Demirezen Yılmaz D
J Biosci Bioeng; 2019 Feb; 127(2):241-245. PubMed ID: 30348486
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women.
Shim JY; Kim MY; Kim YJ; Lee Y; Lee JJ; Jun JK; Shin JC; Cho YK; Lee KY; Kim A; Song TB
BMC Pregnancy Childbirth; 2018 Aug; 18(1):349. PubMed ID: 30153811
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
